Compare INGR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGR | ROIV |
|---|---|---|
| Founded | 1906 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | 721 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 28.7B |
| IPO Year | 1997 | 2021 |
| Metric | INGR | ROIV |
|---|---|---|
| Price | $96.94 | $35.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $128.57 | $28.94 |
| AVG Volume (30 Days) | 526.0K | ★ 8.7M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 15.14 | N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $7,219,000,000.00 | $8,260,000.00 |
| Revenue This Year | $3.86 | N/A |
| Revenue Next Year | $2.95 | $744.61 |
| P/E Ratio | $24.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $94.44 | $14.86 |
| 52 Week High | $123.49 | $42.50 |
| Indicator | INGR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 34.58 | 40.85 |
| Support Level | $94.44 | $33.15 |
| Resistance Level | $105.06 | $37.12 |
| Average True Range (ATR) | 1.85 | 1.45 |
| MACD | -0.34 | -0.52 |
| Stochastic Oscillator | 15.32 | 4.15 |
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins. The company plans to acquire Tate & Lyle in an all-cash deal that should close in 2027.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.